Aura Biosciences, Inc. (AURA) - Uzoq muddatli qarzning kapitalga nisbati
Aura Biosciences, Inc. (AURA) barqaror pul oqimiga ega emas, chunki barcha resurslar ilmiy tadqiqotlarga yo'naltirilgan, bu esa operatsion faoliyatni beqaror qiladi. Asosiy o'sish katalizatori kam uchraydigan ko'z o'smiklariga qarshi dori vositalarining yaqin orada o'tkaziladigan yakuniy sinovlari bo'ladi, bunda joriy ko'rsatkich 0.04 ni tashkil etadi. Ushbu narxlar grafigi bemorlar ko'rish qobiliyatini saqlab qolish uchun virusli terapiyani ishlab chiqayotgan biotexnologiya firmasining profilini to'ldiradi.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_AURA_-_Aura-Biosciences-Inc._-_Long-Term-Debt-to-Equity "aurabiosciences.com (AURA): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 04.07.2022dan 01.11.2026gacha | 👁️GURU.Markets👁️")
Aura Biosciences, Inc. kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Aura Biosciences, Inc.|AURA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati aurabiosciences.com|AURA - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Aura Biosciences, Inc.|AURA - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Aura Biosciences|Tezkor likvidlik koeffitsiyenti aurabiosciences.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning umumiy tahlili:Aura Biosciences Inc - AURA
Ushbu koeffitsiyent kapital tuzilmasidagi uzoq muddatli qarzlar ulushini o'lchab, moliyaviy leveraj darajasini va kompaniyaning uzoq muddatli rejalashtirishda tashqi kreditlarga bo'lgan bog'liqligini belgilaydi. Aura Biosciences, Inc. (AURA) uchun uzoq muddatli qarzning kapitalga nisbati tahlili modelning barqarorligini tasdiqlaydi, bunda onkologiya platformalarining patent himoyasi va FDA qo'llab-quvvatlashi, hatto klinik sinovlar uchun yuqori xarajatlar mavjud bo'lganda ham, defolt risklarini minimallashtiradi.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati SLS (SELLAS Life Sciences Group)|ACTU - Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR: Uzoq muddatli qarzning o'z kapitaliga nisbati|HURA - Uzoq muddatli qarzning kapitalga nisbati|Protara Therapeutics, Inc. (TARA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Fate Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati TScan TCRX|Uzoq muddatli qarzning kapitalga nisbati CSBR|Uzoq muddatli qarzning kapitalga nisbati xbiotech.com (XBIT)|CEL-SCI - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati OS Therapies Inc. OSTX|RADX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti ARTV (Artiva Biotherapeutics, Inc.)|ANL: Uzoq muddatli qarzning kapitalga nisbati|verupharma.com (VERU) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati TPST|XLO: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati RENB|Uzoq muddatli qarzning o'z kapitaliga nisbati MURA (muraloncology.com)|Uzoq muddatli qarzning kapitalga nisbati KAPA (Kairos Pharma)|Uzoq muddatli qarzdorlikning kapitalga nisbati OnKure Therapeutics, Inc. (OKUR)|GDTC - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Curis, Inc.|apollomicsinc.com (APLM) - Uzoq muddatli qarzning o'z kapitaliga nisbati|THAR - Uzoq muddatli qarzdorlikning kapitalga nisbati|ADVB (Advanced Biomed Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati genprex.com (GNPX)|Uzoq muddatli qarzning kapitalga nisbati CLDI|Uzoq muddatli qarzdorlikning kapitalga nisbati Sunshine Biopharma Inc.|Uzoq muddatli qarzning kapitalga nisbati XBIO (Xenetic Biosciences, Inc.)|Salarius Pharma (SLRX) - Uzoq muddatli majburiyatlarning kapitalga nisbati|PPBT - Uzoq muddatli qarzning o'z kapitaliga nisbati|AONC (American Oncology Network) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|BGNE: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Checkpoint Therapeutics Inc.|ELEV (Elevation Oncology, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati iCAD Corp ICAD|Uzoq muddatli qarzning o'z kapitaliga nisbati Ikena Oncology, Inc. (IKNA)|Uzoq muddatli qarzdorlikning kapitalga nisbati notablelabs.com|Viracta Therapeutics, Inc. - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti MOR|NAYA Bio - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Ascentage AAPGV